GSK.L - GSK plc

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
+20.00 (+1.48%)
At close: 06:28PM BST
Stock chart is not supported by your current browser
Previous close1,347.60
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Avg. volume8,500,893
Market cap56.003B
Beta (5Y monthly)0.28
PE ratio (TTM)12.55
EPS (TTM)1.09
Earnings date26 Jul 2023
Forward dividend & yield0.56 (4.13%)
Ex-dividend date18 May 2023
1y target estN/A
  • Business Wire

    GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US

    PHILADELPHIA, June 01, 2023--GSK announces the COiMMUNITY Initiative to help achieve higher adult vaccination rates in the US

  • Reuters

    India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps

    India's GlaxoSmithKline Pharmaceuticals Ltd reported an 8.6% fall in its pre-tax profit for the fourth quarter on Wednesday, hurt by the government's curbs on pricing of some essential medicines. Consolidated profit before tax dropped to 1.90 billion rupees ($23.23 million) for the quarter ended March 31, from 2.08 billion rupees a year earlier, the Indian unit of UK's GSK Plc said in an exchange filing. Revenue from operations at the maker of Augmentin antibiotic and T-Bact ointment fell 2.7% to 7.87 billion rupees.

  • Business Wire

    BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition

    MONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl

  • Yahoo Finance UK

    Trending tickers: GSK | THG | Beazley | Disney

    The latest investor updates on stocks that are trending on Friday.

  • Yahoo Finance UK

    Wall Street loses ground as FTSE 100 closes higher on UK economy growth

    FTSE 100 closes the week higher as the UK economy returned to growth.

  • Motley Fool

    The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

    Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.

  • Yahoo Finance Video

    GSK’s vaccine against RSV wins FDA approval

    Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss the FDA’s approval of GlaxoSmithKline’s (GSK) vaccine against RSV.

  • Business Wire

    US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

    PHILADELPHIA, May 03, 2023--US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

  • The Telegraph

    Investors may be sceptical, but this unloved stock has much to offer – and a lowly valuation

    Here is an unloved stock that offers a new group structure, the potential resolution of legal woes, the presence of an activist investor, a clear strategy, a building pipeline of vaccines and medicines – and all with a lowly valuation.

  • Yahoo Finance

    Pfizer to shift focus to new products amid decline in COVID sales

    Pfizer reported strong earnings for the first quarter of the year, despite a decrease in COVID product demand. However, investors are wary of the company's anticipated product launches this year.

  • Yahoo Finance Video

    Why the human genome could be health care’s holy grail

    23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the company’s partnership with GlaxoSmithKline (GSK) ends in July. Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe

  • Yahoo Finance

    23andMe CEO: We see more opportunities in DNA partnerships

    23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.

  • Motley Fool

    Was This Acquisition a Savvy Play by This Big Pharma Stock?

    Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. Should GSK's deal for Bellus Health be approved by regulatory authorities and a two-thirds majority of the latter's shareholders, the former will pick up a promising drug candidate, camlipixant, that aims to treat refractory chronic cough (RCC). Surprisingly, there are no approved therapies for RCC in the United States or the European Union.

  • Zacks

    GSK (GSK) Tops Q1 Earnings Estimates

    Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Yahoo Finance UK

    Trending tickers: Microsoft | Alphabet | First Republic | Meta | GSK

    A look at the stocks making headlines on Wednesday.

  • Reuters

    GSK stays strong as healthy sales beat expectations

    LONDON (Reuters) -GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results thanks to strong sales of its vaccines as well as HIV and respiratory medicines. In recent quarters the British drugmaker, which carved out its consumer health business Haleon last year, has begun to reverse years of underperformance relative to its peers and bounce back after largely missing out on the market for COVID-19 vaccines. Even after stripping out one-off contributions, underlying revenue and earnings beat expectations by a respectable 3% and 4% respectively, Citi analyst Andrew Baum wrote in a note.

  • Motley Fool

    Why Shares of Bellus Health Skyrocketed This Week

    Shares of Bellus Health (NASDAQ: BLU) jumped 105.1% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The company, which received a $2 billion buyout offer from GSK (formerly known as GlaxoSmithKline) (NYSE: GSK), closed at $7.06 last week and reached a new 52-week high at $14.50 on Tuesday. The attraction for GSK is camlipixant, Bellus' late-stage pipeline candidate to treat adults with refractory chronic cough (RCC).

  • Business Wire

    GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

    LONDON, April 18, 2023--GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion). The acquisition provides GSK access to camlipixant

  • Motley Fool

    Why BELLUS Health Stock Is Rocketing Higher Today

    What happened Shares of BELLUS Health (NASDAQ: BLU) were up by a whopping 98.9% as of 10:19 a.m. ET Tuesday morning. The big gain came in response to a $2 billion buyout agreement with British pharma giant GSK (NYSE: GSK).

  • Motley Fool

    Is Arrowhead Pharmaceuticals a Buy Now?

    The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.

  • Reuters

    GSK's antibiotic drug to treat uncomplicated UTIs meets main goals

    The drug, gepotidacin, in phase III trials, met its primary goals of being on a par or better than nitrofurantoin, the current standard of care for the treatment of uUTIs, the company said. "Gepotidacin, if approved, will offer a much-needed additional oral treatment option for patients at risk of treatment failure associated with resistance or recurrence of uUTI," Chris Corsico, senior vice president of development at GSK, said.

  • Motley Fool

    Can Pfizer Beat GSK and Moderna in This $10 Billion Market?

    Pfizer (NYSE: PFE) and GSK (NYSE: GSK) have competed against each other for years. Moderna (NASDAQ: MRNA) is a more recent rival, with its COVID-19 vaccine, SpikeVax, going head to head with Pfizer's Comirnaty. Can Pfizer beat GSK and Moderna in this $10 billion market?

  • Motley Fool

    Why Shares of Adaptimmune Therapeutics Jumped Tuesday

    Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO cell therapy programs. Adaptimmune focuses on therapies to treat cancer in solid tumors through its SPEAR (for Specific Peptide Enhanced Affinity Receptor) T-cell platform. The company has four SPEAR T-cells in trials: MAGE-A10, MAGE-A4, AFP, and NY-ESO.

  • Motley Fool

    Could This Move by Johnson & Johnson Equal Billions for Moderna?

    What does big pharma Johnson & Johnson (NYSE: JNJ) have in common with biotech Moderna (NASDAQ: MRNA)? Last week, however, Johnson & Johnson said it would discontinue its adult RSV program. Could the J&J news eventually translate into billions of dollars for Moderna?

  • Reuters

    GSK sees $500 million peak sales for yeast infection pill licensed from Scynexis

    LONDON (Reuters) -British drugmaker GSK sees peak sales of more than $500 million for a drug to treat yeast infections that it licensed from U.S. biotech company Scynexis in a $90 million deal announced on Wednesday, a top GSK executive said. The pill, Brexafemme, made just $1.6 million in revenues in the third quarter of last year, according to the most recent financial results from Scynexis, which specialises in anti-fungal treatments. But GSK's Chief Commercial Officer Luke Miels told journalists he was confident that, as a big pharma company with experience building awareness among doctors and patients, GSK could change the trajectory of the product over time.